Yang, V. W-C |
------>authors3_c= ------>paper_class1=6 ------>Impact_Factor=None ------>paper_class3=0 ------>paper_class2=0 ------>vol= ------>confirm_bywho=wpdeng ------>insert_bywho=vyang ------>Jurnal_Rank=None ------>authors4_c= ------>comm_author= ------>patent_EDate=2019-07-02 00:00:00 ------>authors5_c= ------>publish_day=2 ------>paper_class2Letter=None ------>page2= ------>medlineContent= ------>unit=000 ------>insert_date=20050506 ------>iam=1 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=-44 ------>journal_name= ------>paper_name=Peptide inhibitor of fibrinogen blood clotting, US6413931 ------>confirm_date=20080501 ------>tch_id=090071 ------>pmid=19736157 ------>page1= ------>fullAbstract=AIMS: Our study sought to evaluate mechanisms of the current strategies for optimal anticoagulation during percutaneous coronary intervention (PCI). METHODS AND RESULTS: Thirty-two high risk acute coronary syndrome patients were randomised to bivalirudin and provisional GPIIb/IIIa inhibition (GPIIb/IIIa) or unfractionated heparin (UFH) and mandatory GPIIb/IIIa. Flow cytometric measurements immediately after anticoagulation showed that, unlike UFH, bivalirudin did not activate platelets as indicated by P-selectin expression and fibrinogen binding while decreasing platelet-monocyte aggregates and monocyte expression of tissue factor. UFH released tissue factor pathway inhibitor (TFPI) during and immediately after PCI while bivalirudin (irrespective of GP IIb/IIIa) did not. Lower levels of TFPI with bivalirudin were seen during and immediately after PCI (P<0.01). Thrombin generation as indicated by prothrombin fragment F 1+2 levels was reduced during PCI in the UFH group (P<0.01) but not with bivalirudin. Soluble CD40 ligand is associated with thrombosis and levels were higher in the bivalirudin group irrespective of GPIIb/IIIa at the same stages (P<0.05). CONCLUSIONS: Bivalirudin has some early advantages on platelet activation when compared to UFH. However, there are significant limitations in its mechanism of action, particularly a lack of release of tissue factor pathway inhibitor. ------>tmu_sno=None ------>sno=11191 ------>authors2=Hook, M ------>authors3= ------>authors4= ------>authors5= ------>authors6= ------>authors6_c= ------>authors=Yang, V. W-C ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=USA ------>no= ------>patent_SDate=2002-07-02 00:00:00 ------>update_bywho=None ------>publish_year=2002 ------>submit_flag=None ------>publish_month=7 |